Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MREO 
Mereo BioPharma Group PLC ADR (MREO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: MREO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.09
1 Year Target Price $7.09
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.97% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 318.19M USD | Price to earnings Ratio - | 1Y Target Price 7.09 |
Price to earnings Ratio - | 1Y Target Price 7.09 | ||
Volume (30-day avg) 8 | Beta 0.39 | 52 Weeks Range 1.47 - 4.72 | Updated Date 10/16/2025 |
52 Weeks Range 1.47 - 4.72 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1950.8% |
Management Effectiveness
Return on Assets (TTM) -35.13% | Return on Equity (TTM) -74.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 270624605 | Price to Sales(TTM) 636.39 |
Enterprise Value 270624605 | Price to Sales(TTM) 636.39 | ||
Enterprise Value to Revenue 541.25 | Enterprise Value to EBITDA -1.21 | Shares Outstanding 159096881 | Shares Floating 502348402 |
Shares Outstanding 159096881 | Shares Floating 502348402 | ||
Percent Insiders 0.96 | Percent Institutions 68.99 |
Upturn AI SWOT
Mereo BioPharma Group PLC ADR
Company Overview
History and Background
Mereo BioPharma Group PLC was founded in 2015 and focuses on developing and commercializing innovative therapeutics that aim to improve outcomes for patients with rare diseases. It leverages a unique approach to drug development, focusing on clinical-stage assets acquired from larger pharmaceutical companies.
Core Business Areas
- Oncology: Develops treatments for various cancer types using innovative therapies, including etigilimab and alvelestat.
- Rare Diseases: Focuses on developing treatments for rare and debilitating diseases with unmet medical needs.
- Endocrinology: Developing treatments for endocrine disorders.
Leadership and Structure
The leadership team is comprised of experienced professionals in the pharmaceutical industry. The organizational structure includes departments focused on research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Setrusumab (BPS-804): An investigational monoclonal antibody for the treatment of osteogenesis imperfecta (OI) in pediatric and adult patients. Market share data is not publicly available; competitive treatments include bisphosphonates and emerging therapies. Competitors include Ascendis Pharma.
- Alvelestat: A small molecule inhibitor targeting neutrophil elastase (NE) for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) and Bronchiolitis Obliterans Syndrome (BOS) following Hematopoietic Stem Cell Transplant (HSCT). Market share data is not publicly available; competitors include Grifols Prolastin.
- Etigilimab: An anti-TIGIT antibody targeting tumors for the treatment of cancers. Market share is not currently applicable, as it is still in development. Competitors include Roche, Merck, and Bristol-Myers Squibb.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and dynamic, driven by innovation, regulatory changes, and market demand for novel therapies. The rare disease segment is experiencing significant growth due to increasing awareness and regulatory incentives.
Positioning
Mereo BioPharma is positioned as a company focused on acquiring and developing clinical-stage assets with significant potential in niche markets, particularly in rare diseases and oncology. Their competitive advantage lies in their ability to efficiently develop and commercialize assets acquired from larger pharmaceutical companies.
Total Addressable Market (TAM)
The TAM for rare diseases is estimated to be over $170 billion. Mereo is positioned within this market, targeting specific indications within OI, AATD-LD, BOS and oncology.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Focus on clinical-stage assets
- Strong pipeline of potential products
- Efficient development approach
Weaknesses
- Reliance on external funding
- High risk associated with clinical trials
- Competition from larger pharmaceutical companies
- Limited commercial infrastructure
Opportunities
- Potential for partnerships and collaborations
- Expansion into new therapeutic areas
- Accelerated regulatory pathways for rare diseases
- Increasing market demand for innovative therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from generic drugs
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- Ascendis Pharma (ASND)
- Grifols SA (GRFS)
- Roche Holding AG (RHHBY)
- Merck & Co., Inc. (MRK)
Competitive Landscape
Mereo BioPharma was a smaller player competing with large pharmaceutical companies. Their advantage was in their nimble approach and focus on acquired clinical-stage assets, while their disadvantage was in their limited resources and commercial infrastructure.
Major Acquisitions
Aucxis B.V.
- Year: 2023
- Acquisition Price (USD millions): 447
- Strategic Rationale: The acquisition by Aucxis B.V. provided Mereo with increased capital and resouces to aid them in advancing the ongoing projects.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been driven by advancement of the product pipeline through clinical trials and securing strategic partnerships. No revenue data can be provided as of 2024 due to the company being acquired.
Future Projections: Future growth projections are dependent on the acquirer's plans. No publicly available information on future growth projections.
Recent Initiatives: The most recent initiative was the acquisition of the company.
Summary
Mereo BioPharma was a biopharmaceutical company focused on rare diseases and oncology. Their strength was in their strategic acquisition and development of clinical-stage assets. They relied on external funding and faced challenges with clinical trial outcomes and competition from larger pharmaceutical companies. However, it provided a high future potential through its unique assets. After acquisition, the future prospects now lies in the direction of the acquirer.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry News
- Yahoo Finance
- SEC Filings
- Bloomberg
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. The financial data is based on the period before the company was acquired. The AI-based rating is based on an algorithm and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mereo BioPharma Group PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-04-24 | Co-Founder, CEO & Executive Director Dr. Denise Vera Scots-Knight Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.mereobiopharma.com |
Full time employees 36 | Website https://www.mereobiopharma.com | ||
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.